...
atai-img

ATAI Life Sciences BV, Common Stock

ATAI

NMQ

$1.48

-$0.05

(-3.27%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$266.81M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.16M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.78
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.03 L
$2.85 H
$1.48

About ATAI Life Sciences BV, Common Stock

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameATAISectorS&P500
1-Week Return-7.5%-1.8%-0.77%
1-Month Return-6.33%-3.48%0.71%
3-Month Return18.4%-7.2%8.81%
6-Month Return12.12%-1.54%12.32%
1-Year Return28.7%8.39%30.57%
3-Year Return-86.57%6.07%29.21%
5-Year Return-92.39%44.07%91.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-19.88M20.38M233.00K314.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":97.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.14,"profit":true},{"date":"2023-12-31","value":1.54,"profit":true}]
Cost of Revenue6.00K24.00K47.00K168.00K319.00K[{"date":"2019-12-31","value":1.88,"profit":true},{"date":"2020-12-31","value":7.52,"profit":true},{"date":"2021-12-31","value":14.73,"profit":true},{"date":"2022-12-31","value":52.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(6.00K)(24.00K)20.33M65.00K314.00K[{"date":"2019-12-31","value":-0.03,"profit":false},{"date":"2020-12-31","value":-0.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.32,"profit":true},{"date":"2023-12-31","value":1.54,"profit":true}]
Gross Margin-(0.12%)99.77%27.90%100.00%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.12,"profit":false},{"date":"2021-12-31","value":99.77,"profit":true},{"date":"2022-12-31","value":27.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses8.17M92.14M140.70M144.66M125.78M[{"date":"2019-12-31","value":5.65,"profit":true},{"date":"2020-12-31","value":63.69,"profit":true},{"date":"2021-12-31","value":97.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.95,"profit":true}]
Operating Income1.57M(104.16M)(135.81M)(144.79M)(125.47M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-6617.66,"profit":false},{"date":"2021-12-31","value":-8628.02,"profit":false},{"date":"2022-12-31","value":-9198.67,"profit":false},{"date":"2023-12-31","value":-7971.47,"profit":false}]
Total Non-Operating Income/Expense(19.02M)(74.09M)(591.00K)10.15M85.60M[{"date":"2019-12-31","value":-22.23,"profit":false},{"date":"2020-12-31","value":-86.55,"profit":false},{"date":"2021-12-31","value":-0.69,"profit":false},{"date":"2022-12-31","value":11.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(17.47M)(101.81M)(136.60M)(135.18M)(39.29M)[{"date":"2019-12-31","value":-1747400000,"profit":false},{"date":"2020-12-31","value":-10181300000,"profit":false},{"date":"2021-12-31","value":-13660100000,"profit":false},{"date":"2022-12-31","value":-13518200000,"profit":false},{"date":"2023-12-31","value":-3928600000,"profit":false}]
Income Taxes2.00K305.00K(3.99M)6.23M1.02M[{"date":"2019-12-31","value":0.03,"profit":true},{"date":"2020-12-31","value":4.9,"profit":true},{"date":"2021-12-31","value":-64.04,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":16.31,"profit":true}]
Income After Taxes(17.48M)(102.12M)(132.61M)(141.41M)(40.30M)[{"date":"2019-12-31","value":-1747600000,"profit":false},{"date":"2020-12-31","value":-10211800000,"profit":false},{"date":"2021-12-31","value":-13261200000,"profit":false},{"date":"2022-12-31","value":-14141100000,"profit":false},{"date":"2023-12-31","value":-4030200000,"profit":false}]
Income From Continuous Operations(24.38M)(178.63M)(174.24M)(141.41M)(71.40M)[{"date":"2019-12-31","value":-2438400000,"profit":false},{"date":"2020-12-31","value":-17862500000,"profit":false},{"date":"2021-12-31","value":-17424400000,"profit":false},{"date":"2022-12-31","value":-14141100000,"profit":false},{"date":"2023-12-31","value":-7140200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(17.48M)(102.12M)(132.61M)(141.41M)(40.22M)[{"date":"2019-12-31","value":-1747600000,"profit":false},{"date":"2020-12-31","value":-10211800000,"profit":false},{"date":"2021-12-31","value":-13261200000,"profit":false},{"date":"2022-12-31","value":-14141100000,"profit":false},{"date":"2023-12-31","value":-4022400000,"profit":false}]
EPS (Diluted)0.160.01(1.77)(0.98)(0.82)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":3.24,"profit":true},{"date":"2021-12-31","value":-1124.52,"profit":false},{"date":"2022-12-31","value":-622.62,"profit":false},{"date":"2023-12-31","value":-520.97,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ATAI
Cash Ratio 2.29
Current Ratio 5.81

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ATAI
ROA (LTM) -25.41%
ROE (LTM) -62.77%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ATAI
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ATAI
Trailing PE NM
Forward PE NM
P/S (TTM) 806.06
P/B 1.80
Price/FCF NM
EV/R 603.20
EV/Ebitda 0.27

FAQs

What is ATAI Life Sciences BV share price today?

ATAI Life Sciences BV (ATAI) share price today is $1.48

Can Indians buy ATAI Life Sciences BV shares?

Yes, Indians can buy shares of ATAI Life Sciences BV (ATAI) on Vested. To buy ATAI Life Sciences BV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATAI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ATAI Life Sciences BV be purchased?

Yes, you can purchase fractional shares of ATAI Life Sciences BV (ATAI) via the Vested app. You can start investing in ATAI Life Sciences BV (ATAI) with a minimum investment of $1.

How to invest in ATAI Life Sciences BV shares from India?

You can invest in shares of ATAI Life Sciences BV (ATAI) via Vested in three simple steps:

  • Click on Sign Up or Invest in ATAI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ATAI Life Sciences BV shares
What is ATAI Life Sciences BV 52-week high and low stock price?

The 52-week high price of ATAI Life Sciences BV (ATAI) is $2.85. The 52-week low price of ATAI Life Sciences BV (ATAI) is $1.03.

What is ATAI Life Sciences BV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of ATAI Life Sciences BV (ATAI) is

What is ATAI Life Sciences BV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ATAI Life Sciences BV (ATAI) is 1.80

What is ATAI Life Sciences BV dividend yield?

The dividend yield of ATAI Life Sciences BV (ATAI) is 0.00%

What is the Market Cap of ATAI Life Sciences BV?

The market capitalization of ATAI Life Sciences BV (ATAI) is $266.81M

What is ATAI Life Sciences BV’s stock symbol?

The stock symbol (or ticker) of ATAI Life Sciences BV is ATAI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top